Hypoglycemia due to 3β-Hydroxysteroid Dehydrogenase type II Deficiency in a Newborn.

Indian Pediatr

Departments of Pediatrics and *Endocrinology, Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal, India. Correspondence to: Dr Mithun Chandra Konar, DE- 290 -1, Giridhari V Apartment, Flat No 3B, 3rd floor, Narayantala (East), Baguiati, Kolkata 700 159, West Bengal, India.

Published: November 2015

Background: 3β-hydroxysteroid dehydrogenase type II deficiency results in decreased production of all three groups of adrenal steroids. Recurrent hypoglycemia as a presenting feature of this disorder has not been reported earlier.

Case Characteristics: A genotypically and phenotypically normal female newborn delivered by in-vitro fertilization presenting with recurrent hypoglycemia. Primary adrenal insufficiency with insignificant mineralocorticoid deficiency and slightly elevated levels of 17-hydro-xyprogesterone, dehydroepian-drosterone sulphate and testosterone.

Outcome: Successfully managed only with corticosteroid replacement.

Message: Congenital adrenal hyperplasia can rarely cause recurrent hypoglycemia in newborns.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13312-015-0758-zDOI Listing

Publication Analysis

Top Keywords

recurrent hypoglycemia
12
3β-hydroxysteroid dehydrogenase
8
dehydrogenase type
8
type deficiency
8
hypoglycemia
4
hypoglycemia 3β-hydroxysteroid
4
deficiency newborn
4
newborn background
4
background 3β-hydroxysteroid
4
deficiency decreased
4

Similar Publications

Objectives: Moebius syndrome (MS) is a rare congenital non-progressive rhombencephalic disorder mostly characterised by abducens and facial nerve palsy, but with a multifaceted clinical presentation. Isolated or multiple pituitary hormone deficiencies in the setting of MS have been occasionally reported, but the simultaneous involvement of three or more hypothalamic-pituitary axes has never been described. We hereby report the case of a girl with MS that showed a co-occurrence of GH-, TSH- and ACTH-deficiency.

View Article and Find Full Text PDF

Background: Nonislet cell tumor hypoglycemia (NICTH) is a rare but serious complication of malignancy. Various causes of this type of hypoglycemia include excessive tumor burden resulting in destruction of the liver or adrenal glands, production of autoantibodies against insulin and tumoral production of incompletely processed IGF-2.

Objectives: Objective of this case report is to explore pathogenic mechanisms for hypoglycemia in hepatocellular carcinoma (HCC), and evidence-based treatment options.

View Article and Find Full Text PDF

Hypoglycemia and hospital mortality in critically ill patients.

Sci Rep

January 2025

Department of Critical Care Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan.

Prior research has indicated that adopting strict glycemic control measures might elevate the risk of hypoglycemia and result in higher mortality rates among critically ill patients. However, there is a lack of studies investigating the incidence of hypoglycemia and its consequential outcomes in real-world clinical settings. This retrospective cohort study was conducted at Taichung Veterans General Hospital, utilizing critical care databases covering the period from 2015 to 2020.

View Article and Find Full Text PDF

We report the case of a 29-year-old male soldier with a time in service above 10 years, found to have asymptomatic long QT syndrome (LQTS), a condition associated with increased risk of potentially fatal ventricular arrhythmias, during a flight physical. A review of his past medical history revealed a transient QT prolongation during an episode of hypoglycemia due to endogenous hyperinsulinism caused by an insulinoma, as an infantryman 7 years earlier; the resolution of the QT prolongation was spontaneous. He was evaluated and considered fit for duty by cardiology.

View Article and Find Full Text PDF
Article Synopsis
  • Ongoing efforts aim to enhance glycemic control in type 1 diabetes, focusing on semaglutide as a potential adjunct to automated insulin delivery therapy in adults.
  • A randomized, double-blind crossover trial was conducted with 28 participants, where semaglutide or placebo was used, showing a significant increase in the time spent within the target glucose range by an average of 4.8 percentage points.
  • No severe complications like diabetic ketoacidosis or hypoglycemia were reported, indicating that semaglutide is a safe and effective option for improving blood sugar levels in this context.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!